Why do ROS1 tumors keep escaping treatment?
ROS1-positive lung cancer is driven by a single abnormal gene fusion that tells cells to grow. Drugs like crizotinib and entrectinib block that signal and work well at first—but tumors eventually find a way around the blockade. The most common escape is a mutation in the ROS1 gene itself, called G2032R, which changes the shape of the drug-binding pocket so the drug can't attach [1][3]. In a 2024 study of patients who progressed on crizotinib, G2032R was the most frequent on-target resistance mutation [4].
But tumors don't just mutate the target—they also activate other growth pathways to bypass ROS1 altogether. In the same 2024 study, off-target changes like MET amplification were common, and the number of resistance mutations accumulated with each line of therapy [4]. This dual strategy—mutating the target and switching to alternative pathways—is why ROS1-positive cancer is a moving target: it adapts in multiple ways at once.
How do next-generation drugs aim to hit the target?
Next-generation ROS1 inhibitors were designed to be smarter and stronger. Repotrectinib, for example, is a next-generation TKI that was specifically engineered to overcome G2032R and other resistance mutations [1]. In the TRIDENT-1 trial, repotrectinib shrank tumors in 79% of patients who had never received a ROS1 TKI, and in 38% of those who had already progressed on one—including 59% of patients with the G2032R mutation [1]. This shows that targeting the most common resistance mutation can restore treatment effectiveness.
Another next-generation drug, taletrectinib, is also designed to hit G2032R while being more selective—it avoids inhibiting a related protein called TRKB, which is thought to cause side effects like dizziness and cognitive issues with repotrectinib [6]. In preclinical models, taletrectinib inhibited both wild-type ROS1 and G2032R-mutant tumors, and it prolonged survival in mice with brain metastases [6]. This suggests that next-generation drugs are not just more potent—they're also being refined to be more tolerable.
What happens when the target moves again?
Even next-generation drugs face new resistance mutations. For example, the ROS1 L2086F mutation confers resistance to type I TKIs (like crizotinib, entrectinib, lorlatinib, and repotrectinib), but type II TKIs like cabozantinib still work [9]. In a 2024 study, cabozantinib showed clinical activity in patients with L2086F-mutant tumors, and structural analysis explained why—it binds differently to the kinase [9]. This means that when one class of drugs fails, switching to a different class can sometimes overcome resistance.
But resistance isn't always a simple mutation. Sometimes tumors activate survival pathways like YAP1, which helps them survive drug exposure even without a new ROS1 mutation [7]. In a patient-derived cell line, blocking YAP1 restored sensitivity to lorlatinib, suggesting that combining a TKI with a YAP1 inhibitor could be a future strategy [7]. This highlights that overcoming resistance may require combination approaches, not just better single drugs.
How do doctors choose the right treatment?
Because resistance mechanisms vary, the best treatment depends on what's driving the tumor at the time of progression. Guidelines recommend re-biopsy (tissue or liquid) to identify the resistance mechanism [3]. If G2032R is present, repotrectinib or taletrectinib are options; if L2086F is found, cabozantinib might work [3][9]. If no on-target mutation is found, off-target pathways may be at play, and adding a MEK inhibitor (like trametinib) to a TKI showed some benefit in a small phase 1 trial [5].
The evidence is clear that no single drug works forever, but the field is moving toward personalized sequencing. As one 2024 review put it, the approach to subsequent therapy depends on the pace and pattern of progression and the known resistance mechanism [8]. This means that the 'moving target' is being met with a moving strategy—each new resistance mechanism is being mapped, and new drugs are being designed to hit it.
About These Sources
This answer is built on 9 peer-reviewed studies — published from 2021 to 2025, 5 from 2024 or later, 6 in Q1 journals, collectively cited 223 times — selected as the most relevant from 11 studies that passed quality screening, drawn from 54 papers retrieved from a database of over 500 million.
Sources used in this answer
Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer
In the TRIDENT-1 trial, repotrectinib produced responses in 79% of TKI-naive ROS1+ NSCLC patients and 38% of those previously treated with one TKI, including 59% of those with the G2032R resistance mutation.
Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.
In a retrospective study of 107 ROS1+ NSCLC patients, resistance mutations accumulated after crizotinib and lorlatinib, with four novel on-target mutations identified (L2010M, G1957A, D1988N, L1982V) that may confer resistance to various TKIs.
ROS1-positive non-small-cell lung cancer
A case report and review of ROS1+ NSCLC discusses the main resistance mechanisms (on-target mutations like G2032R and bypass signaling) and recommends re-biopsy to guide subsequent therapy.
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in <i>ROS1</i> Fusion-Positive Nonsmall Cell Lung Cancer
In a cohort of 107 ROS1+ NSCLC patients, G2032R and MET amplification were the most common on-target and off-target resistance alterations, respectively, and resistance mutations accumulated with sequential TKI therapy.
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
A phase 1 trial combining ceritinib and trametinib in ALK/ROS1+ NSCLC showed a disease control rate of 56% and median progression-free survival of 3.0 months, suggesting some benefit in TKI-resistant disease.
Abstract 5612: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts
Preclinical studies of taletrectinib showed activity against ROS1 wild-type and G2032R-mutant tumors, and prolonged survival in an intracranial model, while being selective against TRKB to reduce CNS side effects.
Abstract 1098: Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer
In a patient-derived ROS1+ cell line, YAP1 activation contributed to lorlatinib resistance, and inhibiting YAP1 restored sensitivity, suggesting a potential combination strategy.
Advances and future directions in <i>ROS1</i> fusion-positive lung cancer
A review of ROS1+ NSCLC emphasizes that resistance to TKIs is inevitable and that subsequent therapy should be guided by the resistance mechanism and clinical context.
TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers
A study found that the ROS1 L2086F mutation confers resistance to type I TKIs but remains sensitive to type II TKIs like cabozantinib, which showed clinical efficacy in patients with this mutation.